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Nova-1 Regulates Neuron-Specific Alternative
Splicing and Is Essential for Neuronal Viability
to regulate a wide variety of neuronal activities, including
the subcellular distribution and protein interactions of
NR1 NMDA receptors (Ehlers et al., 1995, 1998); the
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physiology of glutamate (Sommer et al., 1990), NMDALaboratory of Molecular Neuro-Oncology
(Hollmann et al., 1993), and GABAA (Macdonald, 1995)The Rockefeller University
receptors; and the ability of agrin to induce clusteringNew York, New York 10021
of acetylcholine receptors (Ferns et al., 1992). Alternative
splicing of receptors is so widespread in the brain that
it has been found in all major receptor subtypes, includ-Summary
ing the glycine, GABA (Macdonald, 1995), dopamine (Pi-
cetti et al., 1997), serotonin (Claeysen et al., 1998), opioidWe have combined genetic and biochemical ap-
(Zaki et al., 1996), and metabotropic glutamate (Connproaches to analyze the function of the RNA-binding
and Pin, 1997) receptors, although the physiologic rele-protein Nova-1, the paraneoplastic opsoclonus-myo-
vance of many of these splice variants is not yet certain.clonus ataxia (POMA) antigen. Nova-1 null mice die
In some instances, alternative splicing has been found topostnatally from a motor deficit associated with apo-
generate a striking diversity of receptors. For example,ptotic death of spinal and brainstem neurons. Nova-1
alternative splicing generates over 1000 different recep-null mice show specific splicing defects in two inhibi-
tor isoforms from three neurexin genes (Ullrich et al.,tory receptor pre-mRNAs, glycine a2 exon 3A (GlyRa2
1995; Missler and SuÈ dhof, 1998) and 576 protein variantsE3A) and GABAA exon g2L. Nova protein in brain ex-
from the cSlo potassium channel gene in the avian co-tracts specifically bound to a previously identified
chlea (reviewed by Black, 1998), and may participate inGlyRa2 intronic (UCAUY)3 Nova target sequence, and
regulating the utilization of variable exons in the neuralNova-1 acted directly on this element to increase E3A
cadherin-like genes to create a complex family of cellsplicing in cotransfection assays. We conclude that
surface adhesion proteins (Kohmura et al., 1998; WuNova-1 binds RNA in a sequence-specific manner to
and Maniatis, 1999). The greatest degree of functionalregulate neuronal pre-mRNA alternative splicing; the
diversity can be generated when splicing of individualdefect in splicing in Nova-1 null mice provides a model
exons is regulated as independent eventsÐa single mes-for understanding the motor dysfunction in POMA.
sage that includes ten such alternatively spliced exons
can generate 210 or 1024 different protein products.
Our current understanding of how alternative splicingIntroduction
is regulated in mammalian cells derives almost exclu-
sively from in vitro biochemical studies (Tacke and Man-One of the fundamental mechanisms generating diver-
ley, 1999), which have implicated sequence-specificsity in cells is differential processing of pre-mRNA. Alter-
RNA-binding proteins, including SR- and hnRNP-typenative splicing can determine the subcellular location,
proteins, in splicing regulation. Although these proteinsmolecular interactions, or function of proteins and is
are ubiquitously expressed, alternative splicing can beable to generate different sets of proteins from single
regulated in individual cells by varying their relative lev-RNA precursors. Alternative splicing is particularly evi-
els, as in the cases of the SR protein ASF-SF2 anddent in the nervous system, where it contributes to the
hnRNP A1 (reviewed by Horowitz and Krainer, 1994),complexity of neuronal function.
by regulating their posttranslational modifications (e.g.,
Proof of the importance of alternative splicing in cell
phosphorylation; see Petersen-Mahrt et al., 1999, and
development emerged from a combination of genetic
references therein) and by assembling the multiprotein
and biochemical studies in Drosophila. Alternative splic- complexes of the splicing apparatus (Hertel et al., 1997).
ing mediated by the Sxl protein is necessary and suffi- Ubiquitously expressed RNA-binding proteins have
cient to regulate sex determination (reviewed by Baker, also been found to contribute to the regulation of neu-
1989; Tacke and Manley, 1999). Sxl is one of several ron-specific splice variants. Neuron-specific splicing of
Drosophila sequence-specific RNA-binding proteins that calcitonin-CGRP pre-mRNA is regulated by the general
regulate splicing by either competing for or disrupting factor polypyrimidine tract±binding protein (PTB), in ad-
the binding of general splicing proteins, such as U2AF65 dition to unidentified factors (Lou et al., 1999). Neurons
(Valcarcel et al., 1993). In contrast, Tra/Tra-2 act by at- insert a unique exon into the SH2 domain of c-src to
tracting general splicing proteins to splice sites that are generate the n-src protein, and this involves a number
otherwise poorly utilized (Tian and Maniatis, 1992). of generally expressed RNA-binding proteins, including
Alternative splicing in neurons was first demonstrated PTB, hnRNP F, hnRNP H, and KSRP (Chan and Black,
when a single pre-mRNA encoding calcitonin in thyroid 1997; Min et al., 1997; Chou et al., 1999). Within the
cells was found to be differentially spliced to encode the nervous system, the generation of GABAA g2 exon in-
neuropeptide neurotransmitter CGRP in neurons (Amara cluded (long, g2L) or excluded (short, g2S) forms is regu-
et al., 1982). Alternative splicing was subsequently found lated by PTB and perhaps other proteins (Zhang et al.,
1999). It remains unclear whether the regulation of tis-
sue-specific splicing by general factors is able to ac-* To whom correspondence should be addressed (e-mail: darnelr@
rockvax.rockefeller.edu). count for the absolute differences in the ways in which
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neurons and nonneuronal cells regulate the same mRNAs these mice is likely to be a direct consequence of the
or whether they would be capable of generating the absence of Nova-1. Nova-1 in brain extracts specifically
diversity seen in different types of neurons. recognizes the GlyRa2 (UCAUY)3 sequence motif, and
An interesting set of candidates for mammalian tis- Nova-1 acts directly on the (UCAUY)3 element to upregu-
sue-specific splicing regulators are neuron-specific late utilization of GlyRa2 E3A in cotransfection experi-
RNA-binding proteins identified as paraneoplastic neu- ments. Taken together, these results demonstrate that
rologic disease (PND) antigens (Darnell, 1996; Grabow- Nova-1 is essential for postnatal motor neuron survival,
ski, 1998). The Nova family of proteins were identified where it functions to regulate neuron-specific splicing
as target antigens in the paraneoplastic opsoclonus- of inhibitory receptor pre-mRNAs.
myoclonus ataxia (POMA) syndrome (Luque et al., 1991;
Buckanovich et al., 1993; Yang et al., 1998), a disorder Results
in which motor dysfunction suggests a defect in the
inhibitory control of neurons in the brainstem and spinal Targeted Deletion of the Mouse Nova-1 Gene
cord. Nova proteins harbor three KH-type RNA-binding To assess the significance of Nova interactions with
domains and are expressed exclusively in neurons specific RNA ligands in neurons, we generated Nova-1
within the central nervous system (CNS; Buckanovich null mice. We used homologous recombination to re-
et al., 1993, 1996). Nova proteins are closely related to place the coding sequence of each of the first two
hnRNP E1/E2 (Burd and Dreyfuss, 1994), which regulate Nova-1 exons, including the sequence encoding the ini-
a-globin stability (Ostareck-Lederer et al., 1998) and tiator methionine, with a targeting vector encoding the
hnRNP K, which shuttles RNA transcripts from the nu- neomycin resistance gene, which was flanked by loxP
cleus to the cytoplasm (Michael et al., 1997), and both sites to allow Cre-mediated excision of the selectable
hnRNP K and hnRNP E1/E2 regulate lipoxygenase-15 markers (Figure 1A). In addition, the cassette harbored
mRNA translation in erythrocytes (Ostareck et al., 1997). an IRES-t-lacZ sequence (Mombaerts et al., 1996) to
Other KH-type RNA-binding proteins include the Frag- allow visualization of Nova-1-expressing neurons. After
ile-X mental retardation gene product (Ashley et al., transfection into embryonic stem (ES) cells, 2 of 96
1993; Siomi et al., 1993) and a number of KH domain G418-resistant clones had undergone homologous re-
proteins identified as splicing factors in yeast (MER-1; combination (Figure 1B). These cells were transfected
Engebrecht and Roeder, 1990), Drosophila (PSI; Siebel with a plasmid expressing Cre recombinase (pB5185)
et al., 1995), and mammals (SF1, KSRP; Arning et al., to excise the loxP-HSV-tk-neomycin (LTNL) cassette,
1996; Min et al., 1997). reanalyzed by Southern blot analysis (data not shown),
RNA selection experiments demonstrated that Nova and used for blastocyst injection. Germline transmission
proteins are sequence-specific RNA-binding proteins was obtained in one line, and the genotype was con-
(Buckanovich et al., 1996; Buckanovich and Darnell, firmed by Southern blot (Figure 1C).
1997; Yang et al., 1998). Full-length Nova-1 binds with We analyzed Nova protein expression in wild-type and
low-nanomolar affinity to a stem loop RNA harboring a Nova-1 null mice by Western blot analysis using POMA
sequence-specific motif (UCAUY)3. This sequence led antisera, which recognize all Nova-related antigens. In
to the identification of a candidate Nova-1 RNA target the forebrain, a single band of 52 kDa and several larger
in (GlyRa2) pre-mRNA present in an intron 85 nt up- bands are recognized (Figure 1D), all of which corre-
stream of the inhibitory glycine receptor a2 exon 3A spond precisely to the set of bands immunoprecipitated
(GlyRa2 E3A; Buckanovich and Darnell, 1997). This exon by a Nova-2-specific peptide antibody (Yang et al.,
is alternatively spliced in a mutually exclusive fashion 1998). In the hindbrain, additional bands of 52±55 kDa
with a downstream exon (E3B; Kuhse et al., 1991). Immu-
are evident in wild-type mice, and these bands are re-
noprecipitation of Nova from brain extracts specifically
duced and absent, respectively, in Nova-1 heterozygous
coprecipitated GlyRa2 pre-mRNA (Buckanovich and
and null mice, indicating that they are derived from theDarnell, 1997), providing evidence that a Nova-GlyRa2
Nova-1 gene. This distribution of Nova-1 correspondsprotein-RNA complex forms in neurons. Recent X-ray
with previous immunohistochemical and in situ hybrid-crystallography of a Nova-RNA complex confirms the
ization studies demonstrating that Nova-1 is specificallyspecificity of the interaction between Nova and the core
expressed in the hindbrain, spinal cord, and hypothala-(UCAUY)3 motif (Lewis et al., 2000).
mus and is absent in the forebrain (Buckanovich et al.,In this report, we combine genetic and biochemical
1996; Yang et al., 1998). The distinct Nova-1 bands likelyanalyses of Nova-1 function to examine the hypothesis
correspond to products of alternatively spliced Nova-1that Nova-1 regulates alternative splicing. We generated
transcripts (Buckanovich et al., 1993) or to posttransla-Nova-1 null mice, which are born indistinguishable from
tional modifications of the protein. We conclude thattheir littermates but die after birth with a profound motor
Nova-1 null mice express no Nova-1 protein variantsfailure that correlates with apoptotic death of motor
but are unchanged in their level of expression of Nova-2neurons in the spinal cord and brainstem. Evaluation of
and Nova-2-related proteins.GlyRa2 pre-mRNA splicing in Nova-1 null mice reveals
a specific defect in the utilization of GlyRa2 E3A in the
Nova-1 Is Required for Postnatal Survivalbrainstem and spinal cord but not in the forebrain, a
of Neurons in the Brainstemregion that does not express Nova-1. Moreover, a survey
and Spinal Cordof neuronal exon usage in Nova-1 null mice revealed an
Nova-1 null mice were phenotypically indistinguishableadditional defect in inclusion of the alternatively spliced
from their littermates at birth. Thereafter, they demon-GABAA g2L cassette exon, which is preferentially used
strated progressive motor dysfunction and died an aver-in the brainstem and spinal cord (Zhang et al., 1996).
The defect in GlyRa2 pre-mRNA alternative splicing in age of 7±10 days after birth (Figure 1E). Prior to their
Nova-1 Regulates Neuronal Splicing
361
Figure 1. Generation of Nova-1 Null Mice
(AI) The wild type Nova-1 locus illustrated
contains the first and second coding exons
(dark boxes, with initiator ATG indicated).
(AII) A targeting construct was generated har-
boring a genomic fragment (left: Xba-AlwNI,
1.6 kb) flanking the initiator methionine, an
IRES-t-lacZ LTNL insertion, and an intronic
genomic fragment flanking the second cod-
ing exon (right: SacI-SacI 6kb).
(AIII) The Nova-1 locus following Cre-medi-
ated excision of the LTNL cassette. Restric-
tion sites are indicated for SacI (S), HindIII
(H), Xba (X), AlwNI (A), PacI (P), and EcoRI
(E). The probe (S-X fragment) used for South-
ern blot analysis is indicated.
(B) Southern blot analysis of ES cells trans-
fected with Nova-1 targeting construct. The
Southern blot of ES cell clones digested with
EcoRI was probed with a DNA fragment that
recognized a 7 kb band in the wild-type
Nova-1 locus and a 5 kb band in the recombi-
nant Nova-1 locus. The fidelity of homologous
recombination was confirmed by probing the
blot with a second probe flanking the right
arm of the targeting construct (data not
shown).
(C) Genotypic analysis of Nova-1 null mice.
Southern blot analysis was performed on tail
DNA and digested with SacI, using the
Nova-1 genomic S-X probe described in (A).
The genotypes for the samples are wild-type
(1/1), Nova-1 heterozygous (1/2), and
Nova-1 null (2/2).
(D) Western blot analysis of Nova protein ex-
pression. Extracts of mouse forebrain or hind-
brain were made from wild-type, heterozy-
gous, or Nova-1 null mice; run on SDS±PAGE
gels; and blotted with POMA antisera, which
recognize all Nova protein species (Nova-1
and Nova-2; see Yang et al., 1998).
(E) Survival curve of Nova-1 null mice and
heterozygote and wild-type littermates. Nova-1 null mice die on average between P7 and P10, whereas heterozygote mice are phenotypically
normal and show no difference in survival from wild-type littermates. The ratio of genotypes is approximately 2:1:1 (het:wt:ko), suggesting
there are no embryonic lethal effects in mice lacking Nova-1.
death, Nova-1 null mice exhibited an action-induced nuclei, most notably in CN XII, and in the deep cerebellar
nuclei but was not evident in regions that do not ex-tremulousness and overt motor weakness (Figure 2A),
although they maintained normal responses to sensory press Nova-1, including the dorsal spinal cord (Figures
2F and 2G), neocortex, and hippocampus (data notstimuli. There was no abnormal phenotype in Nova-1
heterozygotes. shown). TUNEL staining revealed that the pyknotic cells
corresponded to cells undergoing apoptotic death (Fig-Pathologic examination of newborn Nova-1 null mice
revealed normal gross structure and histology in the ures 2H and 2I). Since Nova proteins are expressed
exclusively in neurons, these results demonstrate thatforebrain, brainstem, spinal cord, and extra-CNS struc-
tures. Histologic stains for b-galactosidase revealed the hallmark pathologic change in postnatal Nova-1 null
mice is an increase in apoptotic death in hindbrain andweak b-galactosidase reactivity exclusively in CNS re-
gions previously identified by in situ hybridization to ventral spinal cord neurons.
express Nova-1, including the ventral spinal cord, brain-
stem nuclei, deep cerebellar nuclei, and hypothalamus GlyRa2 Splicing in Nova-1 Null Mice
Since GlyRa2 gene expression and physiology in rodent(Buckanovich et al., 1996; Yang et al., 1998; Figure 2C).
These results confirm that our targeting cassette was in- spinal cord and brainstem undergo regulation after the
first week of postnatal life (Kuhse et al., 1991; Bechadeserted accurately into the Nova-1 locus and that Nova-1
null neurons are confined to the subcortical structures et al., 1994; Singer et al., 1998), we bred Nova-1 null
mice into a CD1 genetic background, yielding Nova-1we had previously identified.
Histologic stains of older Nova-1 null mice revealed null mice that lived for an average of 2±3 weeks after
birth. In these mice, the motor phenotype became par-a 4-fold increase in the number of pyknotic cells in the
ventral region of the spinal cord relative to littermates ticularly pronounced after z7±10 days, with weakness
and tremulousness, and with some mice showing clear(Figures 2G and 2D±2F). A survey of different areas re-
vealed that the increase in pyknotic cells was most evi- signs of atrophy in the hindlimbs.
We examined GlyRa2 splicing in postnatal day 16dent in the ventral spinal cord, in specific brainstem
Neuron
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Figure 2. Histopathology of Nova-1 Null Mice
(A) P5 Nova-1 null (top) and wild-type littermate (below). Nova-1 null mice are significantly smaller and were unable to walk without falling
over at this age.
(B) Hematoxylin and eosin staining of a horizontal section of the spinal cord from P5 Nova-1 null mouse. Boxed areas are shown under higher
magnification in (D) and (dotted box) (F).
(C) Horizontal section of the spinal cord after X-gal staining of P5 Nova-1 null mouse. Most of the neurons in the ventral motor column (VC)
but not neurons in the dorsal sensory column (DC) were labeled blue.
(D±F) Solid boxed area in (B) is shown at high magnification in (D). Large numbers of pyknotic cells were observed in the ventral spinal cord
of Nova-1 null mouse (arrows) but not in the dorsal spinal cord (F) or the ventral spinal cord of a wild-type littermate (E).
(G) High magnification photomicrograph of a pyknotic cell in the ventral spinal cord of a Nova-1 null mouse shows typical apoptotic morphology,
including condensed staining of the nucleus. Inset shows quantitation of the number of pyknotic nuclei counted in the dorsal and the ventral
spinal cords from 27 sections each of wild-type and Nova-1 null spinal cords.
(H) TUNEL staining of the pyknotic cells (arrows) in ventral spinal cord of P5 Nova-1 null mouse.
(I) DAPI counter staining of (H).
Scale bar, 125 mm (B); 250 mm (C); 31 mm (D, E, and F); 10 mm (G); and 20 mm (H and I).
(P16) Nova-1 null mice using several complementary To determine the reproducibility of these observa-
methods. First, RNA was RT-PCR amplified using prim- tions, we examined splicing to E3A and E3B in eight
ers specific to GlyRa2 E2 and GlyRa2 E4. Reaction prod- Nova-1 null mice from six different litters and compared
ucts were then digested with restriction enzymes that the results with splicing in normal littermates. In every
specifically recognized sites either in E3A (SspI) or E3B case, RNA from Nova-1 null mice showed a decrease
(BspMI). We confirmed that these enzymes uniquely rec- in the utilization of E3A relative to E3B (Figure 3C). These
ognized E3A or E3B (with .98% specificity; Figure 3AII) results are consistent with our transfection data (see
and digested E2-E4 PCR products with these enzymes below), in which Nova-1 acts to enhance the utilization
to determine E3A and E3B splicing efficiency (Figure of GlyRa2 E3A, while in the absence of Nova-1 in vivo
3AI). In a second method, E3A- and E3B-specific primers there is a relative deficit in the ability of neurons to utilize
were used under reaction conditions in which each the E3A splice site.
primer showed absolute specificity for its respective
exon (Figure 3B). In a third set of experiments, we per-
Specificity of Splicing Defects in Nova-1 Null Miceformed RNase protection assays (see below). Quantita-
We next examined the specificity of the defect in GlyRa2tion of splicing using linear PCR reaction conditions
splicing by comparing the splicing efficiency of six pre-gave highly reproducible results over a range of reaction
viously described alternatively spliced neuronal tran-conditions (input RNA, PCR cycle number) and between
scripts (Figure 4A). Splicing of five of these transcriptsanimals (see below), and demonstrated that the ratio of
was unchanged in Nova-1 null mice relative to their lit-E3A/E3B splicing was decreased in Nova-1 null mice
relative to wild-type littermates by 2-fold. termates, including clathrin light chain B (ClaB), agrin,
Nova-1 Regulates Neuronal Splicing
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Figure 3. Aberrant GlyRa2 Splicing in Nova-1
Null Mice
(AI) RT-PCR analysis of GlyRa2 E3A and E3B
splicing utilization. Spinal cord RNA from a
P16 Nova-1 null mouse and a wild-type lit-
termate was analyzed by RT-PCR using
32P-labeled E2 primer and unlabeled E4
primer followed by SspI restriction digestion
and autoradiography.
(AII) Specificity of the restriction digest assay.
PCR of a cDNA encoding the mature E2-E3A-
E4 mRNA or the E2-E3B-E4 mRNA was di-
gested with SspI. Phosphorimage analysis of
the data revealed that .98% of the E2-E3A-
E4 DNA was digested, while ,2% of the E2-
E3B-E4 DNA was digested. Similar discrimi-
nation of E3A and E3B products was seen
with BspMI digestions (data not shown).
(BI) RT-PCR analysis of GlyRa2 E3A and E3B
splicing utilization. Spinal cord RNA from a
P18 Nova-1 null mouse and a wild-type lit-
termate was analyzed by RT-PCR using
32P-labeled E2 primer and unlabeled E3A or
E3B primer followed by autoradiography.
(BII) Specificity of the assay. cDNA clones
encoding the mature E2-E3A mRNA or the
E2-E3B mRNA were PCR amplified with
32P-labeled E2-E3A or E2-E3B primer sets.
Analysis of this data on a phosphorimager
revealed that E2-E3A or E2-E3B products
could not be detected using the mismatched
primer pair (E2-E3B or E2-E3A primers, re-
spectively).
(C) Reproducibility of the GlyRa2 splicing de-
fect in Nova-1 null mice. Spinal cord RNA
from Nova-1 null mice and their littermates
with indicated genotypes was analyzed as in
(B) for the presence of GlyRa2 E3A and E3B
isoforms. Data are presented as the ratio of E3A/E3B exon usage in each animal. PCR results were linear with respect to RNA input and cycle
number. Actin RNA levels were measured in each sample by RT-PCR and differed by no more than 5%±10% between littermates (data not shown).
mGluR1, ICH-1, and n-src. However, alternative splicing shown). In forebrain of wild-type versus null mice, we
found no differences in alternative splicing for GlyRa2,of the GABAA receptor g2 subunit was significantly al-
GABAA g2L, or ClaB mRNA or in steady-state levels oftered in Nova-1 null mice. The GABAA g2 transcript is
actin or the spinal motor neuron marker choline acetyl-widely expressed in the brain, but the pre-mRNA is alter-
transferase (ChAT) (Figure 5). We conclude that Nova-1natively spliced to include a cassette exon, g2L, prefer-
mediates a specific effect on the alternative splicing ofentially in brainstem and spinal neurons (Zhang et al.,
GlyRa2 and GABAA g2 receptor pre-mRNAs in a cell-1996). Examination of brainstem and spinal cord RNA
autonomous manner.revealed a 2-fold difference in the E3A/E3B GlyRa2
splicing ratio and nearly a 3-fold difference in the g2L/
g2S GABAA g2 splicing ratio in wild-type versus Nova-1 Genotype and Developmental Profile
null mice, averaged over 11 and 9 litters, respectively of Splicing Changes
(Figure 4B). Similar results were obtained with RNase The level of Nova-1 protein varies in a dose-dependent
protection assays (data not shown), although these re- manner in wild-type mice relative to Nova-1 heterozy-
sults were less reliable than RT-PCR in quantitating the gous and null mice (Figure 1D). To assess whether the
low-abundance GlyRa2 splice variants in a tissue sam- splicing defects of GlyRa2 and GABAA g2 RNAs were
ple of high complexity, as anticipated (Foley et al., 1993). dependent on the level of Nova-1 protein, we examined
Although the GlyRa2 and GABAA g2 genes are ex- the utilization of these exons in mice as a function of
pressed throughout the brain, Nova-1 expression is ab- Nova-1 gene dosage. The GABAA g2L splicing defect
sent in rostral structures, including the forebrain and varied from 1.5-fold in heterozygous mice to a 3-fold
sensory thalamus (Buckanovich et al., 1996; Yang et al., change Nova-1 null littermates (Figures 6A and 6B).
1998; Figure 1D). If aberrant GlyRa2 E3A and GABAA GlyRa2 E3A utilization was only abnormal in Nova-1 null
g2L splicing results directly from the lack of Nova-1 in mice, suggesting differences in the degree to which
neurons, splicing of these RNAs should be normal in the the Nova-1 protein is rate limiting for proper splicing of
forebrain and abnormal in the spinal cord of individual GlyRa2 and GABAA g2 pre-mRNAs.
Nova-1 null mice. Specific abnormalities in GlyRa2 and When we examined alternative splicing as a function
GABAA g2 splicing were found in the spinal cord and of age, we found that utilization of the GABAA g2L in-
creased in wild-type mice during the first 3 weeks ofhindbrain but not the forebrain (Figure 5; data not
Neuron
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Figure 5. GlyRa2 and GABAA g2 Alternative Splicing Defects Are
Restricted to Nova-1-Expressing Regions of Brain in Nova-1 Null
Mice
Spinal cord or forebrain RNA was isolated from a P18 (P7 for GABAA
g2) Nova-1 null mice and a wild-type littermate and analyzed for the
indicated splicing products by RT-PCR. Data are presented as in
Figure 3C. Unlike the spinal cord, quantitation of phosphorimager
data using RNA from forebrain revealed no differences in the ratio of
GlyRa2 E3A/E3B and g2L/g2S GABAA exon usage between Nova-1
null animals and wild-type littermates. ClaB alternative splicing
showed no null:wild-type difference in either spinal cord or forebrain.
Quantitation revealed no differences in the steady-state levels of
RNA encoding the motor neuron marker ChAT or actin in Nova-1
null spinal cord relative to wild-type.
Mouse Brain Nova Binds Specifically
to (UCAUY)3 RNA
To evaluate whether the GlyRa2 splicing defect evident
in Nova-1 null mice could be a direct action of Nova-1
on GlyRa2 pre-mRNA, we first examined whether native
Figure 4. Specific Abnormalities in Alternative Splicing of GlyRa2 Nova protein from mouse brain is able to specifically
and GABAA g2 Transcripts in Nova-1 Null Mice bind the GlyRa2 intronic (UCAUY)3 element. Previous
(A) RNA isolated from a P16 Nova-1 null mouse and a heterozygous work demonstrated that immunoprecipitates of Nova
littermate was analyzed by RT-PCR with primers specific to the protein from brain extracts contain GlyRa2 pre-mRNA
indicated genes. All PCR reactions were performed in duplicate (Buckanovich and Darnell, 1997) but did not define the
using minus-RT reactions (data not shown). LCB2 includes and
specific sequence to which Nova bound. To examineLCB3 lacks the neuron-specific EN exon in the ClaB mRNA (Wang
this question, a 90 nt intronic RNA surrounding theand Grabowski, 1996). Agrin0 lacks and agrin19 includes both Z site
GlyRa2 (UCAUY)3 element was transcribed in the pres-exons (Ferns et al., 1992). mGluR1a lacks and mGluR1b contains
an additional exon in the metabotropic glutamate receptor mRNA ence of 32P-UTP and ultraviolet (UV) cross-linked to pro-
(Hollmann and Heinemann, 1994). ICH-1S includes and ICH-1L lacks teins in brain extracts. As a control, we also transcribed
an additional exon in the IL-1b-converting enzyme mRNA (Wang et a mutant GlyRa2 RNA, (UAAUY)3, previously shown notal., 1994). n-src mRNA includes a neuron-specific exon in the c-src
to bind Nova-1 in vitro (Buckanovich and Darnell, 1997).message (Martinez et al., 1987).
These mixtures were RNase treated, and Nova protein(B) Quantitation of the data presented in (A), together with additional
was immunoprecipitated, run on SDS±PAGE gels, andRNA samples (the number of litters examined is indicated by n). The
ratio of long to short alternatively spliced products measured in transferred to nitrocellulose. A 32P-labeled RNA band
wild-type animals relative to the respective ratio in the correspond- superimposable on the 55 kDa Nova protein band was
ing Nova-1 null littermate is presented. For GlyRa2, the ratio of E3A/ seen specifically in immunoprecipitates of extracts
E3B in wild-type versus Nova-1 null littermate is depicted. The bars
cross-linked to the wild-type (UCAUY)3 but not the mu-represent the average change in wild-type:null exon usage for the
tant (UAAUY)3 RNA (Figure 7). This result demonstratesnumber of litters examined; error bars represent the standard devi-
that native neuronal Nova protein specifically binds toation.
the GlyRa2 intronic (UCAUY)3 RNA.
Nova Regulates GlyRa2 Pre-mRNA Alternativedevelopment (Figure 6C), consistent with previous anal-
yses (Wang and Grabowski, 1996; Zhang et al., 1996), Splicing in Cell Lines
We next examined whether Nova-1 is able to directlyand that a deficiency in exon utilization first becomes
apparent at P7 in Nova-1 null mice (Figure 6C). In Nova-1 act on GlyRa2 pre-mRNA to regulate alternative splicing
of the E3A/E3B exons. We generated a minigene con-heterozygous mice, there was again an intermediate
deficit in GABAA g2 usage evident at P7. The GlyRa2 struct consisting of genomic DNA encoding GlyRa2 E2,
E3A, E3B, and E4 and several hundred nucleotides ofE3A/E3B ratio was unchanged in P0±P4 Nova-1 null
mice (,10% difference across multiple littermates) and intronic DNA on either side of these exons (Figure 8A).
To allow us to determine whether Nova-1 acts directlythereafter differed by 2-fold (data not shown).
Nova-1 Regulates Neuronal Splicing
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Figure 6. Changes in GlyRa2 and GABAA g2
Alternative Splicing as a Function of Gene
Dosage and Development
(A) GABAA g2, GlyRa2, and c-src alternative
exon usage in the spinal cords of a P16 Nova-1
null mouse and its heterozygous and wild-
type littermates was analyzed. There was a
significant difference in alternative exon utili-
zation in both the null and heterozygote mice
for the GABAA g2 message, whereas the
GlyRa2 E3A/E3B ratio is only disturbed in the
null mouse. Alternatively spliced n-src mRNA
is unchanged in all three genotypes.
(B) Data obtained from (A) and the indicated
number of additional litters are shown.
GlyRa2, GABAA g2, and n-src alternative exon
usage in Nova-1 null and heterozygote mice
is plotted using the alternative exon ratio of
the wild-type mouse set to 1. Bars represent
the average of the normalized exon use ratio;
error bars indicate the standard deviation.
(C) Developmental change in the GABAA g2L/
g2S exon use ratio. Points represent single
measurements at the indicated develop-
mental times.
on the GlyRa2 intronic (UCAUY)3 element, we also gener- on extracts of a neuroblastoma cell line, N2A, trans-
fected with the wild-type (UCAU) or mutant (UAAU)ated a mutant minigene in which this element was mu-
tated to the nonbinding (UAAUY)3 sequence. These con- GlyRa2 minigene in the presence or absence of pcNova-1.
A Nova-1 dose-dependent increase in splicing to E3Astructs were then transfected into three different cell
lines along with increasing amounts of a plasmid ex- (and compensatory decrease in E3B) is evident in cells
transfected with the wild-type UCAU but not the mutantpressing Nova-1 (pcNova-1).
Nova-1 transfection mediated an increase in GlyRa2 UAAU GlyRa2 minigene. We demonstrated that Nova-1
was present in increasing amounts in cells transfectedE3A splicing in each of the three cell lines tested. Figure
8B illustrates the results of splicing assays performed with increasing amounts of pcNova-1 by Western blot
analysis (Figure 8C).
To confirm these results and analyze splicing to both
E3A and E3B, we repeated independent transfection
experiments in N2A cells (Figure 8D). In cells transfected
with the wild-type UCAU GlyRa2 minigene, Nova-1 re-
producibly increased E3A splicing at the expense of
E3B splicing. Nova-1 mediated a 2-fold increase in E3A
utilization, an effect similar in magnitude to the decrease
in the E3A/E3B splicing ratio seen in Nova-1 null mice
(Figures 3 and 4).
In N2A cells transfected with the mutant UAAU GlyRa2
minigene, splicing to E3A was unchanged relative to
the wild-type minigene (Figure 8D). In the presence of
increasing amounts of Nova, a paradoxical increase in
E3B, at the expense of E3A, was seen. While the mecha-
nism underlying this observation is unclear, a possibleFigure 7. Native Nova Protein Binds to the GlyRa2 (UCAUY)3 El-
ement explanation is that the UAAU mutation allowed detection
An extract of mouse brainstem was incubated with 90 nt 32P-labeled of a cryptic Nova-1 binding site able to mediate an action
RNAs encoding either the GlyRa2 UCAU intronic sequence (lanes on E3B splicing. Taken together, these results demon-
1, 2, 19, and 29) or mutant UAAU RNA (lanes 3, 4, 39, and 4'). Samples strate that the action of Nova to enhance E3A utilization
were UV cross-linked, RNase treated, and immunoprecipitated with
in wild-type UCAU GlyRa2 pre-mRNAs was abolishedeither rabbit anti-Nova serum (lanes 1, 3, 19, and 39) or preimmune
by mutation in the intronic UCAU Nova-binding element.serum (lanes 2, 4, 29, and 49, run on SDS±PAGE gels and transferred
We repeated these experiments in HeLa cells andto a filter for Western blot analysis with POMA antiserum. The same
filter was also exposed directly to X-ray film to detect 32P-labeled 293T cells, two nonneuronal cell lines that do not ex-
RNA (lanes 19±49). The arrow indicates the molecular size of Nova-1. press Nova (Figures 8E and 8F; data not shown).
The strong reactivity present underneath the Nova-1 bands (lanes pcNova-1 cotransfection with the wild-type GlyRa2 min-
1±4) is due to secondary antibody cross-reactivity with rabbit immu-
igene mediated a 2.5-fold increase in E3A splicing innoglobulin G. The z70 kDa band visible in lanes 1 and 3 is a protein
HeLa cells and a 2-fold increase in 293T cells. Somerelated to Nova-2 that immunoprecipitates specifically with POMA
antisera (Yang et al., 1998). additional effects were seen. In HeLa cells, the increase
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Figure 8. Nova-1 Enhances GlyRa2 E3A Splic-
ing in Heterologous Cell Lines
(A) The GlyRa2 minigene used for splicing
assays in transiently transfected cells con-
tains the complete GlyRa2 E2, a shortened
intron 2, the complete genomic sequence sur-
rounding E3A and E3B, a shortened intron 3,
and 233 nucleotides at the 59 end of E4. The
UCAU Nova-1 binding site in intron 2 is indi-
cated by the schematic hairpin loop, and the
UAAU mutant minigene is indicated by an X.
(B) Nova-1-dependent effects on E3A splicing
of the wild-type UCAU and mutant UAAU
GlyRa2 minigenes. RNA from N2A cells trans-
fected with the wild-type or mutant GlyRa2
minigene and the indicated amount of
pcNova-1 plasmid were analyzed as in Fig-
ure 3A.
(C) Western blot using anti-T7 antibody show-
ing the titration of T7-tagged Nova protein
levels after N2A cells were cotransfected with
the GlyRa2 minigene and the indicated
amounts of pcNova-1.
(D) Nova increases the ratio of E3A/E3B splic-
ing from wild-type GlyRa2 pre-mRNA, but this
effect is abrogated in the GlyRa2 mutant
UAAU pre-mRNA. Three independent trans-
fections were performed in which splicing
products (E3A or E3B) were quantitated as in
Figure 3A. Increasing amounts of pcNova-1
were cotransfected with either the wild type
or mutant GlyRa2 minigene, as indicated. Re-
sults are displayed as a ratio of E3A/E3B. The
total amount of spliced product is unchanged
as a result of Nova titration; the increase in
E3A usage is accompanied by a compensa-
tory decrease in E3B utilization (data not
shown). Reaction products were linear with
respect to input cDNA and PCR cycle number (data not shown). Results shown are the average of three independent transfections, and error
bars represent standard deviation. Similar results were obtained in two additional experiments (data not shown).
(E and F) Nova facilitates E3A splicing in HeLa (E) and 293T (F) cells specifically in wild-type UCAU GlyRa2 transcripts. Western blot confirmed
that HeLa and 293T cells did not express Nova and that Nova transfection led to linear increases in Nova protein (data not shown). Results
are the average of two (E) and four (F) independent transfections, and error bars represent standard deviation.
in E3A splicing was at the expense of E3B, while in 293T that Nova-1 functions to regulate alternative splicing in
neurons by binding pre-mRNA in a sequence-specificcells the increase in E3A-spliced product was inversely
proportional to a decrease in an aberrant spliced prod- manner to activate exon inclusion. Nova-1 present in
brain extracts specifically cross-links the sequenceuct that contained neither E3A nor E3B (E2-E4; data not
shown). We also found that in cells transfected with the (UCAUY)3 but not the mutant sequence (UAAUY)3, con-
sistent with previous coimmunoprecipitation experi-mutant UAAU GlyRa2 minigene, in the presence of Nova
there was no increase in E3A splicing but again a para- ments demonstrating that Nova-1 protein binds GlyRa2
pre-mRNA in vivo. In cotransfection assays, GlyRa2 pre-doxical increase in E3B splicing, and in the absence of
Nova there was a small but consistent increase in E3A mRNAs harboring this (UCAUY)3 sequence show a
Nova-1 dose-dependent increase in utilization of thesplicing that is unexplained. Taken together, these ex-
periments demonstrate that Nova-1 is able to act directly alternatively spliced E3A, while mutant pre-mRNAs har-
boring the (UAAUY)3 point mutant do not show this ef-to enhance the inclusion of GlyRa2 E3A in cell lines
and that this action is dependent on the integrity of the fect. In Nova-1 null mice, there is a reciprocal 2-fold
decrease in the ratio of GlyRa2 E3A relative to E3Bintronic UCAU Nova binding site.
splicing. These data provide converging lines of evi-
dence that Nova-1 regulates GlyRa2 splicing by directlyDiscussion
binding to the pre-mRNA in neurons.
We also find a second specific defect in alternativeNova-1 Regulates Mammalian Tissue-Specific
splicing in Nova-1 null mice, which is deficient inclusionAlternative Splicing
of the GABAA g2L exon. The defective exon utilizationWe have combined biochemical and genetic ap-
of g2L and GlyRa2 E3A in Nova-1 null mice, togetherproaches to demonstrate that Nova-1 functions to regu-
with the finding that Nova-1 enhanced E3A utilization inlate alternative splicing in neurons and found that the
heterologous cells, suggests that Nova-1 most likelyabsence of Nova-1 leads to neuronal death in spinal
and brainstem neurons. We provide strong evidence acts to activate GlyRa2 E3A and GABAA g2L exon inclu-
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sion in neurons. An alternative, and not entirely exclu- 1996; Figures 1 and 2). Therefore, the identification of
Nova-1 as a splicing factor provides a mechanism bysive, possibility is that Nova-1 activates splicing indi-
which individual neurons can differentially regulaterectly by competing with a splicing inhibitor. Such an
splicing in a manner qualitatively distinct from that ofinterpretation would be consistent with the observation
other cell types.that Nova action can be antagonized by a newly discov-
In previous studies of the mechanism of neuron-spe-ered brain-enriched variant of PTB (A. D. Polydorides
cific splicing, intronic enhancer elements similar in na-et al., submitted). However, a strictly indirect action of
ture to the GlyRa2 (UCAUY)3 sequences have been iden-Nova appears unlikely, since the action of Nova-1 in
tified. These include multiple elements that promotetransfected cells is abolished by mutation in an intronic
neuron-specific exon inclusion in the c-src, calcitonin/RNA element.
CGRP, GABAA g2, and agrin genes (Black, 1992; ZhangSeveral unanswered questions regarding tissue-spe-
et al., 1996; Wei et al., 1997; Lou et al., 1999). Regulationcific splicing are addressed by the finding that Nova-1
of splicing appears complex given that multiple ele-regulates alternative splicing in neurons. RNA-binding
ments, both positive and negative, influence alternativeproteins such as Sxl and Tra/Tra-2 in Drosophila, identi-
splicing events. For example, in c-src, in addition tofied by genetic approaches, act in a sequence-specific
positive acting signals identified as targets of an RNA-manner to regulate alternative splicing of specific target
binding protein complex involving KSRP, hnRNP F, andtranscripts. However, genetics has not previously been
hnRNP H (Min et al., 1997; Chou et al., 1999), negativeapplied to the study of RNA-binding proteins in mam-
elements are found in the polypyrimidine tract, upstreammals, and biochemical studies applied to complex splic-
of the neuronal n-src exon, that interact with PTB (Chaning problems have led not to the identification of tissue-
and Black, 1997) and downstream of the n-src exonspecific splicing factors, but to the identification of
that interact with brain-enriched PTB (D. L. Black et al.,ubiquitously expressed RNA-binding proteins. These
submitted).studies have yielded one clear model in which differen-
The mechanism of neuron-specific splicing in thetial regulation of splicing in mammals is generated
GABAA g2 gene has similar complexities (Ashiya et al.,through relatively subtle changes in the levels of such
1995; Zhang et al., 1996, 1999). A number of negativeubiquitous splicing factors. For example, changing the
elements surrounding the g2L exon were found to bindratio of the constitutively expressed hnRNP protein
PTB, and evidence was also found for positive actinghnRNP A1 to the SR protein ASF-SF2 mediates quantita-
splicing elements. These observations, together withtive changes, ranging from 1.25-fold to severalfold in
our data, suggest that Nova-1 may act in concert withcell transfection studies, in the utilization of proximal
general factors such as PTB or brain-enriched PTB toversus distal splice site choices at alternatively spliced
regulate GABAA g2L exon utilization, which would beexons (Caceres et al., 1994). Our data demonstrate that
consistent with the finding that Nova interacts with brainin addition to the role general factors play in regulating
PTB (A. D. Polydorides et al., personal communication).alternative splicing, tissue-specific factors that recog-
GABAA g2L is preferentially included in the hypothala-nize specific RNA ligands exist in mammals. A working
mus, midbrain, brainstem, and spinal cord (Zhang et al.,model for Nova action is that it acts to enhance utilization
1996), and this correlates precisely with the pattern ofof adjacent exons by recruiting general factors, such as
Nova-1 expression, supporting our finding of a role forSR proteins, to promote the assembly of a splicing-
Nova-1 in generating the g2L splice variant in vivo.competent complex.
Nova-1, Neuronal Death, and Neurologic Disease
Nova-1 Regulates Neuron-Specific Several recent reports have implicated splicing defects
Alternative Splicing as a cause of motor neuron death in the spinal cord.
Three families of strictly neuron-specific RNA-binding Dreyfuss and colleagues have determined that a protein
proteins have been identified. Musashi proteins are ex- mutated in the human disorder spinal muscular atrophy
pressed in mitotic neuronal precursors (Sakakibara et plays a critical role in the generation of snRNPs and
al., 1996) and play a role in the early development of have suggested that the proper regulation of splicing
the nervous system in Drosophila. Nova (Buckanovich is necessary for postnatal survival of motor neurons
et al., 1993; Yang et al., 1998) and Hu (Szabo et al., 1991) (Fischer et al., 1997). In addition, Lin et al. (1998) have
proteins were identified as PND target antigens. These reported that splicing defects in the glutamate trans-
autoimmune neurologic disorders are believed to be porter EAAT2 are associated with the motor neuron dis-
triggered when proteins normally sequestered from im- order amyotrophic lateral sclerosis. The phenotype of
mune surveillance in neurons are ectopically expressed Nova-1 null mice, which phenocopies many aspects of
in tumor cells (Darnell, 1996, 1998), leading to the devel- the human POMA syndrome (see below), together with
opment of antigen-specific antibodies and T cells (Dar- the biochemical evidence presented here, provides a
nell, 1996; Albert et al., 1998, 1999). particularly compelling case illustrating splicing defects
Detailed analysis of the developmental and adult ex- that are associated with neuronal death in the ventral
pression patterns of both Nova (Buckanovich et al., spinal cord.
1993, 1996) and Hu (Okano and Darnell, 1997; Waka- Our results demonstrate that Nova-1 is essential for
matsu and Weston, 1997) antigens revealed that their neuronal viability in mature neurons in postnatal mice.
expression is entirely restricted to neurons throughout Nova-1 null neurons appear to undergo normal morpho-
development. Nova-1 expression is not only specific to genesis, assessed histochemically, and axon pathfind-
neurons, but to a subset of neurons in the hypothalamus, ing, assessed by electron microscopy of the neuromus-
cular junction at birth (J. Sanes and R. B. D., unpublishedbrainstem, and spinal cord (Buckanovich et al., 1993,
Neuron
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data). However, the TUNEL-positive and pyknotic nuclei (Lewis et al., 1999; R. B. D. et al., unpublished data).
Moreover, data from the crystal structure of Nova KH3we observed in P5 Nova-1 null neurons reflect the end
stage of apoptotic neuronal death, and it is difficult to be (Lewis et al., 1999) and the Nova KH3-RNA complex
(Lewis et al., 2000) demonstrate that Nova proteins di-certain at what age the neurons become dysfunctional.
Moreover, we cannot rule out the possibility that Nova-1 merize, even when bound to RNA.
Neurons are likely to utilize some immune system-likemay also play a role in early neuronal development. For
example, Nova-2 is expressed together with Nova-1 in mechanism to generate diversity from a relatively small
number of primary transcripts (Darnell, 1998). The signif-early postmitotic neurons and is downregulated in Nova-
1-expressing neurons postnatally, suggesting that Nova-2 icance of a neuron-specific system that regulates alter-
native splicing is that it provides a means for the genera-could rescue Nova-1 function before birth. The defect
in neuronal viability suggests either a loss of function, tion of such diversity. While genome rearrangements
might occur in the brain (see Gao et al., 1998; Kohmurasuch as a failure of mechanisms necessary to ensure
survival of mature neurons, or a gain of function, such as et al., 1998; Serafini, 1999; Wu and Maniatis, 1999), to
date alternative splicing and RNA editing are the onlyacquisition of a new toxic activity that mediates neuronal
death in Nova-1 null neurons. For example, aberrant relevant mechanisms known to operate in neurons.
Nova proteins, acting in concert with other proteins,splicing of the a1A calcium channel in mice is believed
to result in a gain-of-function mutation, which leads to are likely to play an important role in generating the
complexity of neuronal function.a delayed onset neurologic disorder manifest by ataxia,
motor seizures, and absence seizures (Fletcher et al.,
1996). In Nova-1 null mice, defects in inhibitory receptor
Experimental Proceduressplicing could lead to a gain of function, such that gly-
cine and/or GABA receptors become toxic, for example, Plasmid Constructs
by creating imbalances between the neuronal inhibition The GlyRa2 minigene (cloned in pCDNA3, Invitrogen) corresponds to
and excitation that lead to excitotoxic cell death. the following GlyRa2 E2 mouse genomic sequences: bases 81±276
(GenBank accession number X75842), 63±583 (GenBank accessionPatients with POMA have symptoms that suggest ab-
number X75843), and 10±300 (GenBank accession number 75844).normal inhibitory control over brainstem and spinal mo-
The mutated GlyRa2 minigene, in which the Nova-1 binding sitetor pathways (Luque et al., 1991). For example, opsoclo-
59-UCAUCAUCAUUUUCAUUUUGUUU-39 was mutated to 59-UAA
nus is thought to result from failure of normal functioning UAAUAAUUUUAAUUAAGGUU-39, was generated by PCR. A cDNA
of brainstem inhibitory glycinergic neurons, termed om- encoding T7-tagged Nova-1 was cloned into pcXHook (Invitrogen).
nipause neurons (Averbuch-Heller and Remler, 1996), All DNA constructs generated by PCR were sequenced in their en-
tirety.and brainstem or spinal myoclonus is believed to relate
to a failure of inhibition of motor neurons and may involve
GABAergic or glycinergic systems (Rothwell, 1995; Cavi- PCR Primers
ness, 1996; Rajendra et al., 1997). Moreover, mice with The primers used were E2 F, 59-AGCTTTCTGCAAAGACCATGAC;
the spasmodic mutation (Ryan et al., 1994; Saul et al., E4 R, 59-GAAGATCTCCAAATCCAAGGAATCATCTGGG; a2Gly R
E3A, 59-CATGGTGGTTTCTGTGACTGATC; a2Gly R E3B, 59-CATTG1994) and humans with hyperekplexia (Shiang et al.,
TAGTTTCTGCTATTGACCCAAAG; a2Gly R E4, 59-TCCAAATCCAA1993) harbor defects in inhibitory glycine receptors and
GGAATCATCTGGG; actin F, 59-GTGGGCCGCTCTAGGCACCA;suffer from myoclonic syndromes that bear marked simi-
actin R, CCCCCCTGAACCCTAAGGCCAACCG; mGluR1 F, 59-CCT
larities to the motor symptoms evident in Nova-1 null GGGGTGCATGTTTACTCC; mGluR1 R, 59-AGGCCGTCTCGTTGGT
mice and in POMA patients. Thus, the defects in splicing CTTCA; ICH-1 F, 59-GTCTCATCTTCATCAACTCC; ICH-1 R, 59-ATG
of the inhibitory glycine and GABA receptors in Nova-1 CTAACTGTCCAAGTCTA; ClaB F, 59-ACCGAACAGGAGTGGCG
GGAG; ClaB R, 59-GGGGTCTCCTCCTTGGATTCT; g2 GABA F,null mice suggest a reasonable model for the mecha-
59-GTATGGCACCCTGCATTATTTTGTC; g2 GABA R, 59-TTGAATGnism of motor dysfunction in both the murine and human
GTTGCTGATCTGGGACG; ChAT F, 59-ATGCCTATCCTGGAAAAsystems. In POMA, immunologic targeting of Nova pro-
GGTCCC; ChAT R, 59-AGTGCTCCGAGCAAAGATCACAG; src F,
tein may lead to defects in inhibitory receptor function 59-CCAAGCTCTTCGGAGGCTTCAACTC; src R, 59-CACATAGTTGC
and thereby to the excess motor activity evident in the TGGGGATGTAACCG; agrin F, 59-GGGATAGTTGAGAAGTCAGTGG
disorder. GGG; and agrin R, 59-CGAAGCCAGCGGTTGGTGTTG.
Complexity of Regulation of Neuronal Generation of Targeted Mutation
Alternative Splicing Genomic clones encoding Nova-1 were isolated from a phage library
derived from a 129 mouse (Stratagene). A 1.8 kb Xba-AlwNI fragmentThe identification of the glycine and GABAA receptor
encoding sequences upstream of the initiator methionine and a 6.5pre-mRNAs as Nova-1 targets raises the question of
kb SacI fragment harboring sequences downstream of the secondthe extent to which Nova proteins are used to regulate
coding exon were cloned into pBS2 (Stratagene). A PacI linker wasalternative splicing in neurons. The Nova gene family
ligated to a unique NotI site between these fragments to allow insert
itself consists of at least two (Buckanovich et al., 1993; of the IRES-t-lacZ LTNL cassette (Mombaerts et al., 1996). Plasmid
Yang et al., 1998) and possibly additional Nova gene was linearized with SalI and used to electroporate ES cells, which
were grown as described (Mombaerts et al., 1996), including 150family members (Fletcher et al., 1997; Yang et al., 1998;
mg/ml of G418 starting 24 hr after transfection. Genomic DNA fromsee also Figure 1), and the Nova-1 and Nova-2 tran-
individual colonies was digested with EcoRI and screened by South-scripts are themselves alternatively spliced (Buckano-
ern blot with a 59 Nova-1 genomic probe (0.5 kb SacI-XbaI fragment).vich et al., 1993; Yang et al., 1998). Evaluation of Nova
Clones that had undergone homologous recombination were trans-
protein±protein interactions using biochemical and yeast fected with a plasmid expressing Cre recombinase (pB5185) to ex-
two-hybrid assays suggests that Nova-1 and Nova-2 cise the LTNL cassette. Accurate homologous recombination in pos-
itive clones was confirmed by Southern blot with HindIII-digestedcan form homo- and heterotypic protein interactions
Nova-1 Regulates Neuronal Splicing
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genomic DNA and a 39 Nova-1 genomic probe (0.75 kb SacI frag- treatment of activated T cells in the cerebrospinal fluid of patients
with paraneoplastic cerebellar degeneration. Ann. Neurol., in press.ment). A homologous recombinant clone was injected into C57/BL6
blastocysts to produce germline chimeras. Amara, S.G., Jonas, V., Rosenfeld, M.G., Ong, E.S., and Evans, R.
(1982). Alternative RNA processing in calcitonin gene expression
generates mRNAs encoding different polypeptide products. NatureHistology and TUNEL Assay
298, 240±244.The mice were perfused with 4% buffered formaldehyde, and the
brains were removed, postfixed overnight, and embedded in paraffin Arning, S., GruÈ ter, P., Bilbe, G., and Kramer, A. (1996). Mammalian
blocks. Tissue sections (14 mm) were deparaffinized, rehydrated, splicing factor SF1 is encoded by variant cDNAs and binds to RNA.
stained with hematoxylin and eosin, and visualized by light micros- RNA 2, 794±810.
copy using a Zeiss Axioplan microscope. Pyknotic neurons were Ashiya, M., Zhang, L., and Grabowski, P.J. (1995). Regulated splicing
quantitated by counting all pyknotic cells in each of 27 14 mm thick of gamma2 pre-messenger RNA in neuronal cells. Nucleic Acids
sections of spinal cord from a single Nova-1 null mouse or a single Symp. Ser. 33, 215±216.
wild-type littermate. For X-gal staining, whole-mount staining was
Ashley, C.T., Wilkinson, K.D., Reines, D., and Warren, S.T. (1993).performed as described (Mombaerts et al., 1996).
FMR-1 protein: conserved RNP family domains and selective RNAApoptosis was assessed by the DNA terminal transferase nick
binding. Science 262, 563±566.end translation method, or TUNEL assay, as described previously
Averbuch-Heller, L., and Remler, B. (1996). Opsoclonus. Semin. Neu-(Fuks et al., 1995), and visualized by fluorescence microscopy.
rol. 16, 21±26.
Baker, B.S. (1989). Sex in flies: the splice of life. Nature 340, 521±524.RNA Preparation and RT-PCR
Bechade, C., Sur, C., and Triller, A. (1994). The inhibitory neuronalPurified RNA (Chomcynski and Sacchi, 1987) was reverse tran-
glycine receptor. Bioessays 16, 735±744.scribed using random hexamers, and cDNA products were amplified
using PfuTurbo (Stratagene) with 40 pmol of each primer and 0.5 Black, D.L. (1992). Activation of c-src neuron-specific splicing by
pmol of one g-32P-ATP-labeled primer. PCR products were con- an unusual RNA element in vivo and in vitro. Cell 69, 795±807.
firmed by sequencing. PCR was linear with respect to input cDNA Black, D.L. (1998). Splicing in the inner ear: a familiar tune, but what
and cycle number (data not shown). are the instruments? Neuron 20, 165±168.
T7 Transcription and UV Cross-Linking
Buckanovich, R.J., and Darnell, R.B. (1997). The neuronal RNA bind-RNAs for crosslinking were generated by PCR using the wild-type
ing protein Nova-1 recognizes specific RNA targets in vitro and inor mutant GlyRa2 minigene, followed by in vitro transcription. The
vivo. Mol. Cell. Biol. 17, 3194±3201.primers used were T7primer1 (sense) (59-AGTAATACGACTCACT
Buckanovich, R.J., Posner, J.B., and Darnell, R.B. (1993). Nova, theATAGGGATCATGCAGTTCTGGTTTAAT) and primer2 (antisense)
paraneoplastic Ri antigen, is homologous to an RNA-binding protein(59-AGCTCCATCAACATCTGTGG), which amplified a 90 nt fragment
and is specifically expressed in the developing motor system. Neu-surrounding the Nova-1 binding site. Gel-purified PCR products
ron 11, 657±672.were used as templates for in vitro transcription. Thirty microliters
of total cell extracts from mouse brainstem (50 ml/mg) were irradiated Buckanovich, R.J., Yang, Y.Y., and Darnell, R.B. (1996). The onco-
with UV light for 15 min. The samples were treated with 80 U of neural antigen Nova-1 is a neuron-specific RNA-binding protein,
RNAse A (Worthington) for 30 min at 378C. UV cross-linking reactions the activity of which is inhibited by paraneoplastic antibodies. J.
were immunoprecipitated with a 5 ml polyclonal rabbit anti-Nova-1 Neurosci. 16 1114±1122.
antisera in a total volume of 100 ml of lysis buffer. The immune Burd, C.G., and Dreyfuss, G. (1994). Conserved structures and diver-
complexes were precipitated with protein A±Sepharose beads sity of functions of RNA-binding proteins. Science 265, 615±621.
(Sigma), run on 10% SDS±PAGE gels, transferred to nitrocellulose,
Caceres, J.F., Stamm, S., Helfan, D.M., and Krainer, A.R. (1994).
and exposed to film.
Regulation of alternative splicing in vivo by overexpression of antag-Cell Transfection
onistic splicing factors. Science 265, 1706±1709.N2A, HeLa, and 293T cells were grown to 60% confluence in 35
Caviness, J.N. (1996). Myoclonus. Mayo Clin. Proc. 71, 679±688.mm dishes or in 6-well plates. 2.5 mg of total DNA, comprised of
0.25 mg of the wild-type or mutant pcDNA3 GlyRa2 minigene, 0.25 Chan, R.C., and Black, D.L. (1997). The polypyrimidine tract binding
mg of pCMV b-galactosidase, and variable amounts of pcNova-1 protein binds upstream of neural cell±specific c-src exon N1 to
and empty pcXHook vector, were incubated with 95 ml of Dulbecco's repress the splicing of the intron downstream. Mol. Cell. Biol. 17,
modified Eagle's medium (DMEM) and 5 ml of Fugene (Roche) for 4667±4676.
15 min at room temperature. The mixture was then added to the Chomcynski, P., and Sacchi, N. (1987). Single-step method of RNA
cells in a total volume of 2 ml 10% FBS-DMEM. After 48 hr, the cells isolation by acid guanidinium thiocyanate-phenol-chloroform ex-
were collected and used for RNA extraction, protein extraction, and traction. Anal. Biochem. 162, 156±159.
b-galactosidase assay. Western blot analysis and b-galactosidase
Chou, M.Y., Rooke, N., Turck, C.W., and Black, D.L. (1999). hnRNPassays were performed as described (Okano et al., 1999).
H is a component of a splicing enhancer complex that activates a
c-src alternative exon in neuronal cells. Mol. Cell. Biol. 19, 69±77.
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